Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fused heterocyclic compound

a heterocyclic compound and compound technology, applied in the field of pyrimidine compound, can solve the problems of poor prognostic factor, poor receptor expression, high expression and simultaneous expression of each of these receptors, and achieve the effect of superior tyrosine kinase inhibitory action, high drug satisfaction, and low toxicity

Inactive Publication Date: 2009-01-15
TAKEDA PHARMA CO LTD
View PDF18 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a compound with superior tyrosine kinase inhibitory action. The compound has low toxicity and is satisfactory as a pharmaceutical product. The compound can be represented by the formula (I) or a salt thereof. The compound has been found to have superior inhibitory action against various tyrosine kinases, including BCR-ABL, c-Src, and EGFR. The compound can be used as a prodrug and has been shown to have good pharmacokinetic properties.

Problems solved by technology

It is also known that high expression and simultaneous expression of each of these receptors are poor prognostic factors in various cancer patients.
Moreover, receptor expression and prognosis are correlated, and receptor expression is a poor prognostic factor in breast cancer, non-small cell lung cancer and the like.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fused heterocyclic compound
  • Fused heterocyclic compound
  • Fused heterocyclic compound

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

Production of 2-[(2-chloro-4-nitrophehoxy)methyl]benzonitrile

[0320]To a solution of 2-chloro-4-nitrophenol (3.5 g) and 2-(bromomethyl)benzonitrile (4.0 g) in N,N-dimethylformamide (50 mL) was added potassium carbonate (3.7 g), and the mixture was stirred at room temperature for 30 min. After the completion of the reaction, water (50 mL) was added, and the mixture was stirred for 10 min. The resultant pale-yellow solid was collected by filtration. The residue was washed with diisopropyl ether, and dried to give the title compound (5.04 g) as pale-yellow crystals.

[0321]1H-NMR (CDCl3) δ 5.44 (2H, s), 7.13 (1H, d, J=9.0 Hz), 7.51 (1H, dt, J=1.2, 7.2 Hz), 7.68-7.80 (3H, m), 8.19 (1H, dd, J=2.7, 9.0 Hz), 8.35 (1H, d, J=2.7 Hz).

reference example 2

Production of 2-[(4-amino-2-chlorophenoxy)methyl]benzonitrile

[0322]To a solution of 2-[(2-chloro-4-nitrophenoxy)methyl]benzonitrile (2.0 g) in ethanol / water (9:1, 40 mL) was added calcium chloride (90%, 427 mg), and the mixture was stirred at 100° C. for 10 min. Reduced iron (90%, 2.6 g) was added at room temperature, and the mixture was stirred at 100° C. for 3 hrs. After the completion of the reaction, the reaction mixture was filtered (celite), and the filtrate was concentrated under reduced pressure. Water was added to the residue and the mixture was diluted with ethyl acetate and washed with water and saturated brine. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate:methylene chloride=2:1:1) to give the title compound (1.2 g) as a white solid.

[0323]1H-NMR (CDCl3) δ 3.53 (2H, br s), 5.23 (2H, s), 6.54 (1H, dd, J=2.7, 8.7 Hz), 6.76 (1H,...

reference example 3

Production of 2-[(2-methyl-4-nitrophenoxy)methyl]benzonitrile

[0324]The title compound (8.2 g) was obtained as a pale-yellow solid by the reaction in the same manner as in Reference Example 1 using 2-methyl-4-nitrophenol (5.0 g) and 2-(bromomethyl)benzonitrile (6.4 g).

[0325]1H-NMR (CDCl3) δ 2.37 (3H, s), 5.36 (2H, s), 6.97 (1H, d, J=8.4 Hz), 7.50 (1H, m), 7.65-7.69 (2H, m), 7.76 (1H, td, J=0.9, 7.5 Hz), 8.09-8.14 (2H, m).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
molecular weightaaaaaaaaaa
receptor enzyme activityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a compound represented by the formula:wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Division of application Ser. No. 10 / 592,812, filed Sep. 14, 2006, which is a U.S. National Stage of PCT / JP2005 / 010451, filed Jun. 1, 2005, which applications are incorporated herein by reference.TECHNICAL FIELD[0002]The present invention relates to a fused pyrimidine compound having a growth factor receptor tyrosine kinase inhibitory activity, which is useful for the prophylaxis or treatment of cancer, a production method thereof and use thereof.BACKGROUND ART[0003]The gene of cell growth factor and growth factor receptor is called a protooncogene and plays a key role in the pathology of human tumor. The epithelial cell growth factor receptor family (erbB) includes EGFR, HER2, HER3 and HER4, which are type I receptor type tyrosine kinases. These erbB family express in various cell groups, and are deeply involved in the control of the growth and differentiation of cells and the control of suppression of cell death (ap...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D487/04A61K31/519A61K31/5377A61K31/551A61P35/00A61P43/00C07D487/16
CPCC07D487/16C07D487/04A61P1/18A61P11/00A61P13/08A61P13/12A61P15/00A61P31/18A61P35/00A61P35/02A61P35/04A61P43/00A61P9/00A61P9/10A61K31/5377
Inventor ISHIKAWA, TOMOYASUTANIGUCHI, TAKAHIKOBANNO, HIROSHISETO, MASAKI
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com